Robert Sambursky
Founder chez Rapid Pathogen Screening, Inc.
Profil
Robert P.
Sambursky is the founder of Rapid Pathogen Screening, Inc. (founded in 2004) where he holds the title of President & Director.
He is also the founder of RPS Diagnostics, Inc. (founded in 2004) where he holds the title of President, Chief Executive Officer & Director.
Currently, Dr. Sambursky is the President, Chief Executive Officer & Director at Lumos Diagnostics, Director at Visus Therapeutics, Inc., and President at Versa Holdings LLC.
In the past, Dr. Sambursky served as the Chief Medical Officer at Lumos Diagnostics Holdings Ltd.
in 2022.
Dr. Sambursky's education includes an undergraduate degree from Brown University and graduate and doctorate degrees from Boston University School of Medicine.
Postes actifs de Robert Sambursky
| Sociétés | Poste | Début |
|---|---|---|
Rapid Pathogen Screening, Inc.
 Rapid Pathogen Screening, Inc. Medical/Nursing ServicesHealth Services Rapid Pathogen Screening, Inc. is an emerging biotechnology company strategically focused on designing, developing, and delivering novel point-of-care tests for infectious diseases and inflammatory conditions as well as bio-terrorism and chemical nerve agent blood toxins. The firm’s products include AdenoPlus, InflammaDry, FebriDx. The company was founded by Robert P. Sambursky and Robert W. VanDine in 2004 and is headquartered in Sarasota, FL. | Founder | 01/01/2004 |
RPS Diagnostics, Inc.
 RPS Diagnostics, Inc. Medical SpecialtiesHealth Technology RPS Diagnostics, Inc. develops diagnostic solutions and medical instruments. Its product FebriDx is in-office test that uses a finger stick blood sample to help differentiate viral from bacterial acute respiratory infection. The company was founded by Robert P. Sambursky in 2004 and is headquartered in Sarasota, FL. | Founder | - |
Lumos Diagnostics
 Lumos Diagnostics Medical SpecialtiesHealth Technology Lumos Diagnostics develops and provides diagnostic solutions. It offers assay development, reader development, and point-of-care diagnostic solutions. The company is headquartered in Carlsbad, CA. | Chief Executive Officer | - |
Visus Therapeutics, Inc.
 Visus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Visus Therapeutics, Inc. is a clinical stage biopharmaceutical company that focuses on developing multi-targeted ophthalmic therapeutics for the front and back of the eye. The company is based in Seattle, WA and has subsidiaries in the United States. The company is developing novel, pupil-modulating therapeutics designed to correct the loss of near vision associated with presbyopia. In parallel, Visus is advancing its pipeline of early-stage ophthalmic drug candidates engineered to preserve and restore visual function associated with the leading causes of vision loss including cataract and presbyopia, ocular surface and corneal disease, glaucoma, and age-related macular degeneration. The company was founded by Benjamin Scot Bergo, Rhett M. Schiffman, and Benjamin Scot Bergo has been the CEO since incorporation. | Director/Board Member | - |
Versa Holdings LLC
 Versa Holdings LLC Financial ConglomeratesFinance Versa Holdings LLC provides investment services. The private company is based in Wilmington, DE. | President | 05/08/2022 |
Anciens postes connus de Robert Sambursky
| Sociétés | Poste | Fin |
|---|---|---|
| LUMOS DIAGNOSTICS HOLDINGS LIMITED | Chief Executive Officer | 11/04/2022 |
Formation de Robert Sambursky
| Brown University | Undergraduate Degree |
| Boston University School of Medicine | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| LUMOS DIAGNOSTICS HOLDINGS LIMITED | Health Technology |
| Entreprise privées | 5 |
|---|---|
Rapid Pathogen Screening, Inc.
Rapid Pathogen Screening, Inc. Medical/Nursing ServicesHealth Services Rapid Pathogen Screening, Inc. is an emerging biotechnology company strategically focused on designing, developing, and delivering novel point-of-care tests for infectious diseases and inflammatory conditions as well as bio-terrorism and chemical nerve agent blood toxins. The firm’s products include AdenoPlus, InflammaDry, FebriDx. The company was founded by Robert P. Sambursky and Robert W. VanDine in 2004 and is headquartered in Sarasota, FL. | Health Services |
RPS Diagnostics, Inc.
RPS Diagnostics, Inc. Medical SpecialtiesHealth Technology RPS Diagnostics, Inc. develops diagnostic solutions and medical instruments. Its product FebriDx is in-office test that uses a finger stick blood sample to help differentiate viral from bacterial acute respiratory infection. The company was founded by Robert P. Sambursky in 2004 and is headquartered in Sarasota, FL. | Health Technology |
Versa Holdings LLC
Versa Holdings LLC Financial ConglomeratesFinance Versa Holdings LLC provides investment services. The private company is based in Wilmington, DE. | Finance |
Lumos Diagnostics
Lumos Diagnostics Medical SpecialtiesHealth Technology Lumos Diagnostics develops and provides diagnostic solutions. It offers assay development, reader development, and point-of-care diagnostic solutions. The company is headquartered in Carlsbad, CA. | Health Technology |
Visus Therapeutics, Inc.
Visus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Visus Therapeutics, Inc. is a clinical stage biopharmaceutical company that focuses on developing multi-targeted ophthalmic therapeutics for the front and back of the eye. The company is based in Seattle, WA and has subsidiaries in the United States. The company is developing novel, pupil-modulating therapeutics designed to correct the loss of near vision associated with presbyopia. In parallel, Visus is advancing its pipeline of early-stage ophthalmic drug candidates engineered to preserve and restore visual function associated with the leading causes of vision loss including cataract and presbyopia, ocular surface and corneal disease, glaucoma, and age-related macular degeneration. The company was founded by Benjamin Scot Bergo, Rhett M. Schiffman, and Benjamin Scot Bergo has been the CEO since incorporation. | Health Technology |
